Trial Profile

A single-institution phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Sponsors Astellas Pharma; Pfizer

Most Recent Events

22 Nov 2021 New trial record
08 Nov 2021 Primary endpoint of Proportion of women surviving progression-free for at least 6 months (PFS6)has been met as per Results published in the Gynecologic Oncology
08 Nov 2021 Results published in the Gynecologic Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com